Cancer medicine · 2026
Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non-Small Cell Lung Cancer With ROS1 Rearrangement.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tan Quan-Quan, Chen Yu-Qing, Gao Yu-Er, Liu Ke-Jun, Mao Zi-Ji, Zheng Ming-Ying, Su Jun-Wei, Yang Jiao, Gao Qing-Yun, Chen Hua-Jun, Yang Jin-Ji
Аннотация
BACKGROUND: Crizotinib is the classic first-line treatment for ROS1-rearranged NSCLC. However, data on the clinical progression modes and recommended options for subsequent treatments after crizotinib treatment failure are limited.
METHODS: Twenty-eight patients were categorized into dramatic or gradual/local progression groups. We analyzed the clinical characteristics, survival outcomes, and potential resistance mechanisms in different progression modes.
RESULTS: The median progression-free survival (mPFS) in the dramatic and gradual/local progression groups was 8.0 and 22.0 months, respectively (p < 0.001). The median overall survival (mOS) was 14.2 and 90.3 months in the dramatic progression and gradual/local progression groups, respectively (p < 0.001). Among patients with dramatic progression after crizotinib failure, significant differences were shown in median post-progression overall survival (mpOS) (7.1 vs. 3.6 vs. 1.0 months, p = 0.037) and mOS (23.1 vs. 18.3 vs. 10.6 months, p = 0.002) across subsequent chemotherapy, targeted therapy, or best supportive care (BSC). ROS1 kinase domain point mutations were detected predominantly in the dramatic progression group, while the activation of bypass and downstream pathways occurred in the gradual/local progression group.
CONCLUSION: The progression modes of ROS1 rearrangement may predict survival benefits and provide subsequent treatment strategies in ROS1-rearranged NSCLC.
METHODS: Twenty-eight patients were categorized into dramatic or gradual/local progression groups. We analyzed the clinical characteristics, survival outcomes, and potential resistance mechanisms in different progression modes.
RESULTS: The median progression-free survival (mPFS) in the dramatic and gradual/local progression groups was 8.0 and 22.0 months, respectively (p < 0.001). The median overall survival (mOS) was 14.2 and 90.3 months in the dramatic progression and gradual/local progression groups, respectively (p < 0.001). Among patients with dramatic progression after crizotinib failure, significant differences were shown in median post-progression overall survival (mpOS) (7.1 vs. 3.6 vs. 1.0 months, p = 0.037) and mOS (23.1 vs. 18.3 vs. 10.6 months, p = 0.002) across subsequent chemotherapy, targeted therapy, or best supportive care (BSC). ROS1 kinase domain point mutations were detected predominantly in the dramatic progression group, while the activation of bypass and downstream pathways occurred in the gradual/local progression group.
CONCLUSION: The progression modes of ROS1 rearrangement may predict survival benefits and provide subsequent treatment strategies in ROS1-rearranged NSCLC.